µ¿Á¾À̽ÄÀ¸·Î Ä¡·áÇÑ ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´ Ç×¾Ï Ä¡·á ÈÄ °ñ¼ö ¹«Çü¼ºÁõ 1¿¹
Acute Myeloid Leukemia with Persistent Marrow Aplasia after Chemotherapy Treated with Reduced-Intensity Allogeneic Stem Cell Transplantation
´ëÇѳ»°úÇÐȸÁö 2014³â 86±Ç 2È£ p.242 ~ p.246
À±ÇöÈ(Yoon Hyun-Hwa) - °¡Ãµ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°ú
È«ÁؽÄ(Hong Jun-Shik) - °¡Ãµ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°ú
±è¼ö¿µ(Kim Su-Young) - °¡Ãµ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°ú
À̵¿¹Î(Lee Dong-Min) - °¡Ãµ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°ú
¹ÚÁøÈñ(Park Jinny) - °¡Ãµ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°ú
¾ÈÁ¤¿(Ahn Jeong-Yeal) - °¡Ãµ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø Áø´Ü°Ë»çÀÇÇаú
ÀÌÀçÈÆ(Lee Jae-Hoon) - °¡Ãµ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°ú
Abstract
±Þ¼º °ñ¼ö¼º ¹éÇ÷º´¿¡¼ °í¿ë·® Ç×¾ÏÈÇпä¹ý ÈÄ ¹ß»ýÇÏ´Â Áö¼Ó¼º °ñ¼ö ¹«Çü¼ºÁõÀº ³ôÀº ÀÌȯÀ²°ú »ç¸Á·üÀ» ³ªÅ¸³¾ ¼ö ÀÖ´Â ¸Å¿ì µå¹® ÇÕº´ÁõÀ¸·Î ´õ¿íÀÌ °¨¿°±îÁö µ¿¹ÝÇÑ °æ¿ì´Â ÀϹÝÀûÀ¸·Î Á¶Ç÷¸ð¼¼Æ÷À̽ÄÀÇ ±Ý±âÀ̳ª Àü¹®ÀûÀÎ °¨¿° Ä¡·á¸¦ º´ÇàÇÏ¸é¼ ºñ°ñ¼ö¾ïÁ¦¼º Àüóġ·Î Á¶Ç÷¸ð¼¼Æ÷À̽ÄÀ» Àû±Ø °í·ÁÇØ¾ß ÇÑ´Ù.
Persistent bone marrow aplasia after intensive chemotherapy is uncommon, but is one of the fatal complications in patients with acute myeloid leukemia (AML). Although allogeneic hematopoietic stem cell transplantation (HSCT) is considered to be contraindicated for patients who have hematologic diseases with serious infections, such as bacterial septicemia or invasive fungal diseases, combined with prolonged neutropenia due to frequent morbidity and mortality, such risks can be overcome by non-myeloablative conditioning and best supportive care. Here, we report an AML patient with persistent marrow aplasia after induction therapy, treated successfully with reduced-intensity allogeneic HSCT despite severe bacterial and fungal infections.
Å°¿öµå
±Þ¼º °ñ¼ö¼º ¹éÇ÷º´, Á¶Ç÷¸ð¼¼Æ÷À̽Ä, ¹«Çü¼ººóÇ÷, È£Áß±¸ °¨¼ÒÁõ, Ç×¾ÏÈÇпä¹ý
Acute myeloid leukemia, Stem cell transplantation, Aplastic anemia, Neutropenia, Chemotherapy
KMID :
0882420140860020242
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)